NCT03547973 2026-03-16
TROPHY U-01
Gilead Sciences
Phase 2 Recruiting
Clinical Trials
9 trialsNCT06133517 2026-03-16
PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer
Fundación para el Progreso de la Oncología en Cantabria
Phase 2 Active not recruiting
NCT05335941 2026-03-04
A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05536141 2026-02-27
ARC-20
Arcus Biosciences, Inc.
Phase 1 Recruiting
NCT05891171 2026-02-27
ARC-25
Arcus Biosciences, Inc.
Phase 1 Active not recruiting
NCT07397611 2026-02-09
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
Dana-Farber Cancer Institute
Phase 2 Not yet recruiting
NCT04381832 2025-07-22
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
Arcus Biosciences, Inc.
Phase 1/2 Completed
NCT05915442 2025-05-20
SBRT-AMICO
Columbia University
Phase 2 Recruiting
NCT05177770 2025-05-08
Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
Coherus Oncology, Inc.
Phase 2 Terminated